Crizotinib combined with selumetinib

Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer most commonly arises from EML4 (echinoderm microtubule-like 4)-ALK chromosomal fusion. A clinical study has demonstrated that the combination of the ALK inhibitor crizotinib and the methyl ethyl ketone inhibitor selumetinib is highly effective in reducing the cell viability of cancer cells in ALK-positive non-small cell lung cancer. Crizotinib reduced tumor volume by 52% compared with the control group, and the drug combination reduced tumor growth. Furthermore, MEK inhibition alone reduced tumor growth by 59% compared to controls. However, this study has not yet entered the indications for selumetinib through relevant approval.